[Pulmonary arterial hypertension in intensive care unit and operating room].
OBJECTIVE
To review the perioperative anaesthetic management of pulmonary arterial hypertension.


METHODS
Extraction from Pubmed database of French and English articles on the perioperative anaesthetic management of pulmonary hypertension for 9 years.


METHODS
The collected articles were reviewed and selected according their quality and originality. The more recent data were selected.


RESULTS
Pulmonary arterial hypertension is classically divided in primary and secondary. Primary pulmonary hypertension (familial and sporadic) is relatively severe and rare. Muscularization of the terminal portion of the pulmonary vascular arterial tree, caused by smooth muscle cell hyperplasia is the first change. Pulmonary arterial hypertension linked with disorders of the respiratory system and hypoxemia or pulmonary venous hypertension including mitral valve disease and chronic left ventricular dysfunction are often associated with high morbidity and mortality. The main consequence of pulmonary hypertension development is the occurrence of right-sided circulatory failure. A better understanding of disease pathophysiology will contribute to the development of new therapies increasing then the prognosis of these patients. The management of primary pulmonary hypertension or secondary pulmonary arterial hypertension is a challenge for the anaesthesiologist because the risk of right ventricular failure is markedly increased.
Kerbaul
F
F
Département d'anesthésie-réanimation adultes, CHU de La Timone, 126 rue saint-Pierre, 13385 Marseille cedex 5, France. fkerbaul@yahoo.fr
Rondelet
B
B
Collart
F
F
Naeije
R
R
Gouin
F
F
D000758:Anesthesia / Q000379:methods; D000777:Anesthetics / Q000494:pharmacology; D019090:Case Management; D003422:Critical Care / Q000379:methods*; D015150:Echocardiography, Doppler; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D007431:Intraoperative Complications / Q000517:prevention & control / Q000628:therapy*; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000503:physiopathology; D009569:Nitric Oxide / Q000502:physiology; D010100:Oxygen / Q000008:administration & dosage / Q000627:therapeutic use; D011229:Preanesthetic Medication; D011652:Pulmonary Circulation / Q000187:drug effects; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D012121:Respiration, Artificial / Q000379:methods; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000503:physiopathology; D018497:Ventricular Dysfunction, Right / Q000209:etiology; D016277:Ventricular Function, Left / Q000187:drug effects
D000777:Anesthetics; D014665:Vasodilator Agents; D009569:Nitric Oxide; D010100:Oxygen